Four years after 'moonshot' launch, Patrick Soon-Shiong has a big reveal: a single patient
Biotechs don’t typically unveil clinical data at the JP Morgan conference; it’s a gathering reserved for both the celebration and construction of deals, after all. But for Patrick Soon-Shiong, NantKwest chairman and CEO, it’s befitting.
Soon-Shiong, the inventor of Abraxane and controversial biotech billionaire, took the podium at JPM 2016 to launch a four-year moonshot to “subdue cancer by the start of the next decade.”
Now that 2020 is here, NantKwest is putting forth some new evidence for what it’s calling the “cancer breakthrough 2020”: one complete response in the expanded access portion of a Phase I trial.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 77,000+ biopharma pros reading Endpoints daily — and it's free.